AWM
INBX icon

Avior Wealth Management’s Inhibrx INBX Stock Holding History

Avior Wealth Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-248
Closed -$3.82K – 1511
2024
Q4 		$3.82K Sell
248
-76
-23% -$1.16K ﹤0.01% 1954
2024
Q3 		$5.07K Buy
+324
New +$4.55K ﹤0.01% 1776

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return

Avior Wealth Management's INBX Position: Q1 2025 in Review

Avior Wealth Management sold out of Inhibrx (INBX) in Q1 2025, closing a stake of 248 shares — an estimated $3.82K sold.

Avior Wealth Management first reported a position in INBX in Q3 2024 and held it in 2 quarters. The position peaked at $5.07K in Q3 2024. 92 funds tracked by Wall St. Rank hold INBX as of Q1 2025.

  • Avior Wealth Management reported no remaining Inhibrx position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 248 Inhibrx shares in Q1 2025, an estimated $3.82K.
  • Avior Wealth Management first reported a position in Inhibrx in Q3 2024 and held it in 2 quarters.
  • Avior Wealth Management's Inhibrx position peaked at $5.07K in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Inhibrx as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.